EGOGYN ® is a drug based on ethinyl estradiol + levonorgestrel
THERAPEUTIC GROUP: Systemic hormonal contraceptives - Progestin and estrogens, fixed combination
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications EGOGYN ® - Contraceptive Pill
EGOGYN ® is used as an oral contraceptive.
EGOGYN ® action mechanism - Contraceptive Pill
The presence of levonorgestrel as a progestogen makes EGOGYN ® a second generation oral contraceptive, therefore born with the intent to reduce the most common side effects of oral contraception but still unable to solve problems related to weight gain and skin disorders.
The contraceptive action of the drug is mediated by the presence of estrogens and progestins combined at concentrations such as to guarantee an inhibition of the secretion of gonadotropins, useful to block oocyte maturation and ovulation, and at the same time to vary the chemical-physical characteristics of the mucus cervical and endometrial necessary to counteract spermatozoa along the female genital tract and the possible embryo nesting.
The pharmacokinetic characteristics of the two active ingredients, and in particular the half-life estimated to be over 20 hours, allow the patient to maintain maximum contraceptive coverage simply by taking one tablet a day at the same time every day.
Studies carried out and clinical efficacy
1. LOW DOSAGE CONTRACTORS AND BODY WEIGHT
Study demonstrating that the use of low-dose contraceptives based on ethinyl estradiol and levonorgestrel can guarantee better control of body weight and body composition, contributing to therapeutic compliance
2. ORAL CONTRACTS AND EMOTIONAL WELL-BEING
An interesting study that demonstrates how the marketing of oral contraceptives able to control the side effects of the contraceptive therapy can safeguard both the state of physical health of the woman subjected to the treatment and her emotional well-being.
3. CASE REPORT: CONTRACEPTIVES AND CITOLYTIC HEPATITIS
Case reports showing the probable association between oral contraceptive administration and cytolytic hepatitis onset. These evidences demonstrate the importance of medical supervision throughout the entire treatment period.
Method of use and dosage
EGOGYN ® 0.03mg coated tablets of ethinyl estradiol and 0.150 mg of levonorgestrel:
taking oral contraceptives such as EGOGYN ® follows very precise dosing schedules and characterized by the continuous intake of one tablet a day for 21 days at the same time interspersed with periods of suspensions 7 days long, in which a suspension hemorrhage occurs that resembles to the common menstruation.
The maximum contraceptive power is carried out through the introduction of one tablet a day always at the same time, while this capacity tends to run out gradually after 36 hours from the last intake until it disappears completely after about 7 days of suspension, necessary to restore the physiological hormonal balance.
In case of use of previous hormonal contraceptive methods, recent pregnancies or abortions, taking EGOGYN ® may undergo significant variations.
EGOGYN ® warnings - Contraceptive Pill
As with any oral contraceptive, even for EGOGYN ® a careful gynecological examination is necessary before the administration, in order to clarify the prescriptive appropriateness and the possible presence of contraindications or situations such as to increase the risk of occurrence of side effects.
In fact, given the ability of oral contraceptives to increase the risk of thromboembolic and probably neoplastic events, women suffering from vascular and cardiac problems, risk factors for cardiovascular diseases such as smoking and obesity, changes in liver and kidney function, neurological and psychiatric disorders and pathologies Metabolic drugs such as diabetes should carefully evaluate the cost / benefit ratio of contraceptive therapy with your doctor and possibly set a schedule for periodic monitoring.
In these situations the correct relationship between doctor and patient is fundamental, useful in dispelling any doubts and fears and underlining the need to recognize possible signs, premonitions of more serious pathological conditions.
EGOGYN ® contains lactose so that its intake in patients with lactase enzyme deficiency, glucose / galactose malabsorption or lactose intolerance, could be associated with severe gastrointestinal disorders.
PREGNANCY AND BREASTFEEDING
Given the absence of the correct characterization profile of oral contraceptives when used during pregnancy, the administration of EGOGYN ® is contraindicated during the entire gestational period.
This contraindication also extends to the next stage of breastfeeding, given the ability of both active ingredients contained in EGOGYN ® to pass through the breast filter and concentrate in breast milk.
Interactions
As it is known both ethinylestradiol and levonorgestrel are metabolized at the hepatic level by cytochrome enzymes: an enzymatic group particularly susceptible to the modulating activity of different active principles.
Precisely for this reason, the simultaneous intake of EGOGYN ® and active ingredients such as rifampicin, phenytoin, barbiturates, antiretrovirals, antibiotics, herbal remedies such as St. John's wort, which can alter the activity of the aforementioned enzymes, could determine pharmacokinetic alterations in able to reduce the contraceptive efficacy of the drug.
Consequently the concomitant intake of other drugs must necessarily be preceded by a medical consultation and possibly combined with other methods of contraception coverage.
EGOGYN ® Contraindications - Contraceptive Pill
EGOGYN ® is contraindicated in case of current or previous venous thrombosis, stroke, hypertension, metabolic pathologies such as diabetes mellitus, hypertension and dyslipidemia, alterations in liver and kidney function, malignant pathologies, neuro-psychiatric disorders, motor disorders, undiagnosed gynecological disorders and in case of hypersensitivity to the active ingredient or to one of its excipients.
Undesirable effects - Side effects
Different clinical trials and careful post-marketing monitoring show that taking second-generation oral contraceptives may be associated with the appearance of side effects such as nausea, abdominal pain, weight gain, headache, migraine, mood alterations and increase of breast tenderness with tenderness.
Fortunately, clinically more relevant side reactions such as thromboembolic events, hypertension, coronary heart disease, hyperlipidemia and cholestatic jaundice, have been described exclusively in a few cases and especially in particularly predisposed patients.
Note
EGOGYN ® is salable only under medical prescription.
